% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sannemann:154201,
      author       = {Sannemann, Lena and Schild, Ann-Katrin and Altenstein,
                      Slawek and Bartels, Claudia and Brosseron, Frederic and
                      Bürger, Katharina and Cosma, Nicoleta Carmen and
                      Fliessbach, Klaus and Freiesleben, Silka Dawn and Glanz,
                      Wenzel and Heneka, Michael T. and Janowitz, Daniel and
                      Kilimann, Ingo and Kobeleva, Xenia and Laske, Christoph and
                      Metzger, Coraline D. and Munk, Matthias H. J. and Perneczky,
                      Robert and Peters, Oliver and Polcher, Alexandra and
                      Priller, Josef and Rauchmann, Boris and Rösch, Christina
                      and Rudolph, Janna and Schneider, Anja and Spottke, Annika
                      and Spruth, Eike Jakob and Teipel, Stefan and Vukovich, Ruth
                      and Wagner, Michael and Wiltfang, Jens and Wolfsgruber,
                      Steffen and Düzel, Emrah and Jessen, Frank},
      title        = {{N}europsychiatric symptoms in at-risk groups for {AD}
                      dementia and their association with worry and {AD}
                      biomarkers—results from the {DELCODE} study},
      journal      = {Alzheimer's research $\&$ therapy},
      volume       = {12},
      number       = {1},
      issn         = {1758-9193},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DZNE-2021-00063},
      pages        = {131},
      year         = {2020},
      abstract     = {BackgroundEarly identification of individuals at risk of
                      dementia is mandatory to implement prevention strategies and
                      design clinical trials that target early disease stages.
                      Subjective cognitive decline (SCD) and neuropsychiatric
                      symptoms (NPS) have been proposed as potential markers for
                      early manifestation of Alzheimer’s disease (AD). We aimed
                      to investigate the frequency of NPS in SCD, in other at-risk
                      groups, in healthy controls (CO), and in AD patients, and to
                      test the association of NPS with AD biomarkers, with a
                      particular focus on cognitively unimpaired participants with
                      or without SCD-related worries.MethodsWe analyzed data of
                      n = 687 participants from the German DZNE Longitudinal
                      Cognitive Impairment and Dementia (DELCODE) study, including
                      the diagnostic groups SCD (n = 242), mild cognitive
                      impairment (MCI, n = 115), AD (n = 77), CO
                      (n = 209), and first-degree relatives of AD patients
                      (REL, n = 44). The Neuropsychiatric Inventory
                      Questionnaire (NPI-Q), Geriatric Depression Scale (GDS-15),
                      and Geriatric Anxiety Inventory (GAI-SF) were used to assess
                      NPS. We examined differences of NPS frequency between
                      diagnostic groups. Logistic regression analyses were carried
                      out to further investigate the relationship between NPS and
                      cerebrospinal fluid (CSF) AD biomarkers, focusing on a
                      subsample of cognitively unimpaired participants (SCD, REL,
                      and CO), who were further differentiated based on reported
                      worries.ResultsThe numbers of reported NPS, depression
                      scores, and anxiety scores were significantly higher in
                      subjects with SCD compared to CO. The quantity of reported
                      NPS in subjects with SCD was lower compared to the MCI and
                      AD group. In cognitively unimpaired subjects with worries,
                      low Aß42 was associated with higher rates of reporting two
                      or more NPS (OR 0.998, $95\%$ CI 0.996–1.000,
                      p < .05).ConclusionThese findings give insight into the
                      prevalence of NPS in different diagnostic groups, including
                      SCD and healthy controls. NPS based on informant report seem
                      to be associated with underlying AD pathology in cognitively
                      unimpaired participants who worry about cognitive
                      decline.Trial registrationGerman Clinical Trials Register
                      DRKS00007966. Registered 4 May 2015},
      keywords     = {Aged / Alzheimer Disease: epidemiology / Anxiety:
                      epidemiology / Biomarkers / Cognitive Dysfunction:
                      epidemiology / Humans / Longitudinal Studies /
                      Neuropsychological Tests},
      cin          = {Göttingen common / AG Heneka ; AG Heneka / Patient Studies
                      Bonn / AG Höglinger 1 / AG Teipel / AG Endres / Delcode},
      ddc          = {610},
      cid          = {I:(DE-2719)6000014 / I:(DE-2719)1011303 /
                      I:(DE-2719)1011101 / I:(DE-2719)1110002 / I:(DE-2719)1510100
                      / I:(DE-2719)1811005 / I:(DE-2719)5000034},
      pnm          = {342 - Disease Mechanisms and Model Systems (POF3-342) / 344
                      - Clinical and Health Care Research (POF3-344)},
      pid          = {G:(DE-HGF)POF3-342 / G:(DE-HGF)POF3-344},
      experiment   = {EXP:(DE-2719)DELCODE-20140101},
      typ          = {PUB:(DE-HGF)16},
      pmc          = {pmc:PMC7566134},
      pubmed       = {pmid:33066827},
      doi          = {10.1186/s13195-020-00701-7},
      url          = {https://pub.dzne.de/record/154201},
}